A Non-Interventional, Registry Study for Chinese Gastric Cancer Patients With HER2 Status: Clinical and Pathological Characteristics, Treatment Patterns and Clinical Outcomes (EVIDENCE)

Trial Profile

A Non-Interventional, Registry Study for Chinese Gastric Cancer Patients With HER2 Status: Clinical and Pathological Characteristics, Treatment Patterns and Clinical Outcomes (EVIDENCE)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms EVIDENCE
  • Sponsors Roche
  • Most Recent Events

    • 06 Jun 2017 Results of an interim analysis (n=95) assessing the effectiveness and safety of Trastuzumab in Chinese patients with metastatic gastric cancer, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 17 May 2017 Planned End Date changed from 1 Dec 2017 to 21 Nov 2017.
    • 17 May 2017 Planned primary completion date changed from 1 Dec 2017 to 21 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top